Related Experiment Video
Updated: May 5, 2026

A Strategy to Identify de Novo Mutations in Common Disorders such as Autism and Schizophrenia
Published on: June 15, 2011
Natural history of Sanfilippo syndrome in Spain
Verónica Delgadillo1, Maria del Mar O'Callaghan, Laura Gort
1Neuropediatrics Department, Hospital Sant Joan de Déu, Barcelona, Spain. vdelgadillo@hsjdbcn.org.
Background:
Mucopolysaccharidosis type III (MPS III), or Sanfilippo syndrome, is caused by a deficiency in one of the four enzymes involved in the lysosomal degradation of heparan sulphate. Four MPS III types have been recognized, characterized by a large phenotypic heterogeneity. This is the first Spanish study describing the natural history of Sanfilippo patients (MPSIIIA, MPSIIIB and MPSIIIC), representing an essential step for understanding patient prognosis and for the establishment and application of future therapies.
Methods:
This retrospective study aimed to establish the natural history of MPS III in Spain based on an extensive chronological data survey involving physicians and parents of 55 Spanish MPSIII patients. In addition to clinical description we report biochemical and molecular analysis already performed in the majority of cases.
Results:
The most frequent subtype was MPS IIIA (62%). Symptoms before diagnosis were speech delay in 85%, followed by coarse facial features in 78%, and hyperactivity in 65% of cases at a mean age of 3 years old. The median age at clinical and biochemical diagnosis for each MPS III subtype were as follows: IIIA 4.4 years (1.2 - 16 years), IIIB 3.1 years (1-29 years), and IIIC 6.3 years (3.4-22 years).45% of patients developed epilepsy at a median age of 8.7 (2.5 - 37) years old.Age of death for MPS IIIA patients was 15 years (11.5 - 26 years).Molecular analysis of our cohort reveals, as alluded to above, a great allelic heterogeneity in the three subtypes without clear genotype-phenotype correlations in most cases.
Conclusion:
MPS IIIA is the most frequent subtype in Spanish Sanfilippo patients. Diagnosing physicians should consider Sanfilippo syndrome in children with non-specific speech delay, behavioural abnormalities, and/or mild dysmorphic features. We stress the importance of establishing early diagnosis procedures as soon as possible so as to be able to determine future short-term enzymatic or gene therapy treatments that can change the prognosis of the disease.
Insights
Mucopolysaccharidosis type III (MPS III), or Sanfilippo syndrome, is a rare genetic disorder. This study highlights MPS IIIA as the most common subtype in Spain, emphasizing early diagnosis for better patient outcomes.
Area of Science:
- Genetics and rare diseases
- Lysosomal storage disorders
- Biochemistry of heparan sulfate degradation
Background:
- Mucopolysaccharidosis type III (MPS III), or Sanfilippo syndrome, results from deficiencies in four key enzymes for heparan sulfate lysosomal degradation.
- MPS III exhibits significant phenotypic heterogeneity across its four recognized types.
- This study provides the first description of the natural history of Sanfilippo syndrome in Spain, covering MPS IIIA, MPS IIIB, and MPS IIIC.
Purpose of the Study:
- To establish the natural history of MPS III in a Spanish cohort.
- To understand patient prognosis and inform the development of future therapies.
- To analyze clinical, biochemical, and molecular data for Spanish MPS III patients.
Main Methods:
- Retrospective study design.
- Extensive chronological data collection from physicians and parents of 55 Spanish MPS III patients.
- Inclusion of clinical descriptions, biochemical, and molecular analyses.
Main Results:
- MPS IIIA was the most frequent subtype (62%).
- Common early symptoms included speech delay (85%), coarse facial features (78%), and hyperactivity (65%) around age 3.
- Median diagnosis ages were 4.4 years (IIIA), 3.1 years (IIIB), and 6.3 years (IIIC). Epilepsy developed in 45% of patients around age 8.7.
- Molecular analysis showed significant allelic heterogeneity without clear genotype-phenotype correlations.
Conclusions:
- MPS IIIA is the predominant subtype among Spanish Sanfilippo patients.
- Physicians should suspect Sanfilippo syndrome in children presenting with non-specific speech delay, behavioral issues, or mild dysmorphic features.
- Early diagnosis is crucial for implementing timely enzymatic or gene therapies to improve patient prognosis.
More Related Videos
06:41In Vivo Functional Study of Disease-associated Rare Human Variants Using Drosophila
Published on: August 20, 2019
08:22A Novel Strategy Combining Array-CGH, Whole-exome Sequencing and In Utero Electroporation in Rodents to Identify Causative Genes for Brain Malformations
Published on: December 1, 2017
Related Concept Videos
Cystic Fibrosis: Pathogenesis
CF is primarily caused by a genetic mutation in a chromosome 7 gene coding for the cystic fibrosis transmembrane conductance regulator (CFTR) protein. The most common gene mutation leading to CF is the ΔF508 mutation,...
Lysosomal Hydrolases
Huntington Disease l: Introduction
iPS Cell Differentiation
Pharmacogenomics: Identification of New Drug Targets
Sex-linked Disorders